TY - JOUR
T1 - Strengthening screening for infectious diseases and vaccination among migrants in Europe
T2 - what is needed to close the implementation gaps?
AU - ECDC ad hoc scientific panel
AU - Noori, Teymur
AU - Hargreaves, Sally
AU - Greenaway, Christina
AU - van der Werf, Marieke
AU - Driedger, Matt
AU - Morton, Rachael L.
AU - Hui, Charles
AU - Requena-Mendez, Ana
AU - Agbata, Eric
AU - Myran, Daniel T.
AU - Pareek, Manish
AU - Campos-Matos, Ines
AU - Nielsen, Rikke Thoft
AU - Semenza, Jan
AU - Nellums, Laura B.
AU - Pottie, Kevin
AU - Dias, S
N1 - Funding Information:
SH is funded by the National Institute for Health Research (NIHR Advanced Fellowship NIHR300072), the Academy of Medical Sciences (SBF005\1111), and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) through an ESCMID Study Group for Infections in Travellers and Migrants (ESGITM) research grant. MP is supported by the National Institute for Health Research (NIHR Post-Doctoral Fellowship, PDF-2015-08-102). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the UK Department of Health.
Funding Information:
SH is funded by the National Institute for Health Research ( NIHR Advanced Fellowship NIHR300072 ), the Academy of Medical Sciences ( SBF005\1111 ), and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) through an ESCMID Study Group for Infections in Travellers and Migrants ( ESGITM ) research grant. MP is supported by the National Institute for Health Research ( NIHR Post-Doctoral Fellowship , PDF-2015-08-102 ). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the UK Department of Health.
Publisher Copyright:
© 2020 The Authors
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Migration to the European Union (EU)/European Economic Area (EEA) affects the epidemiology of infectious diseases, including tuberculosis (TB), HIV, hepatitis B/C, and parasitic diseases. Some sub-populations of migrants are also considered to be an under-immunised group and thus at risk of vaccine-preventable diseases. Providing high-risk migrants access to timely and efficacious screening and vaccination, and understanding how best to implement more integrated screening and vaccination programmes into European health systems ensuring linkage to care and treatment, is key to improving the health of migrants and their communities, alongside meeting national and regional targets for infection surveillance, control, and elimination. The European Centre for Disease Prevention and Control (ECDC) has responded to calls to action to improve migrant health and strengthen universal health coverage by developing evidence-based guidance for policy makers, public health experts, and front-line healthcare professionals on how to approach screening and vaccination in newly arrived migrants within the EU/EEA. In this Commentary, we provide a perspective towards developing efficacious screening and vaccination of newly arrived migrants, with a focus on defining implementation challenges and evidence gaps in high-migrant receiving EU/EEA countries. There is a need now to leverage the increasing momentum around migrant health to both strengthen the evidence-base and to advocate for universal access to health care for all migrants in the EU/EEA, including undocumented migrants. This should include voluntary, confidential, and non-stigmatising screening and vaccination that should be free of charge and facilitate linkage to appropriate care and treatment.
AB - Migration to the European Union (EU)/European Economic Area (EEA) affects the epidemiology of infectious diseases, including tuberculosis (TB), HIV, hepatitis B/C, and parasitic diseases. Some sub-populations of migrants are also considered to be an under-immunised group and thus at risk of vaccine-preventable diseases. Providing high-risk migrants access to timely and efficacious screening and vaccination, and understanding how best to implement more integrated screening and vaccination programmes into European health systems ensuring linkage to care and treatment, is key to improving the health of migrants and their communities, alongside meeting national and regional targets for infection surveillance, control, and elimination. The European Centre for Disease Prevention and Control (ECDC) has responded to calls to action to improve migrant health and strengthen universal health coverage by developing evidence-based guidance for policy makers, public health experts, and front-line healthcare professionals on how to approach screening and vaccination in newly arrived migrants within the EU/EEA. In this Commentary, we provide a perspective towards developing efficacious screening and vaccination of newly arrived migrants, with a focus on defining implementation challenges and evidence gaps in high-migrant receiving EU/EEA countries. There is a need now to leverage the increasing momentum around migrant health to both strengthen the evidence-base and to advocate for universal access to health care for all migrants in the EU/EEA, including undocumented migrants. This should include voluntary, confidential, and non-stigmatising screening and vaccination that should be free of charge and facilitate linkage to appropriate care and treatment.
KW - Europe
KW - Infection
KW - Migrants
KW - Screening
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85097401855&partnerID=8YFLogxK
U2 - 10.1016/j.tmaid.2020.101715
DO - 10.1016/j.tmaid.2020.101715
M3 - Article
C2 - 32389827
AN - SCOPUS:85097401855
VL - 39
JO - Travel Medicine and Infectious Disease
JF - Travel Medicine and Infectious Disease
SN - 1477-8939
M1 - 101715
ER -